GlassScriptPhysician profile
Ramin S Pakbaz
NPI 1811072457
$33,473.62
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $3,088 · 2021: $9,236 · 2022: $323.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $10,916.53 | 2019-2022 | |
| Medtronic USA, INC. | $8,991.94 | 2019-2020 | |
| Medtronic, INC. | $8,373.69 | 2021-2022 | |
| Silk Road Medical, INC. | $3,812.21 | 2019 | |
| Microvention, INC. | $912.28 | 2019-2021 | |
| Stimwave Technologies Incorporated | $210.21 | 2019 | |
| Depuy Synthes Sales INC. | $105.09 | 2019 | |
| Biosense Webster, INC. | $92.53 | 2019 | |
| Stryker Corporation | $22.16 | 2019 | |
| Medtronic Vascular, INC. | $20.85 | 2019 | |
| Nevro Corp. | $16.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Pakbaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.